Bluejay Diagnostics (NASDAQ:BJDX – Get Free Report) and NeuroPace (NASDAQ:NPCE – Get Free Report) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their earnings, institutional ownership, profitability, valuation, analyst recommendations, risk and dividends.
Earnings and Valuation
This table compares Bluejay Diagnostics and NeuroPace”s gross revenue, earnings per share and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Bluejay Diagnostics | $250,000.00 | 14.12 | -$7.72 million | ($125.15) | -0.02 |
| NeuroPace | $79.91 million | 4.01 | -$27.14 million | ($0.84) | -11.52 |
Insider and Institutional Ownership
18.5% of Bluejay Diagnostics shares are held by institutional investors. Comparatively, 78.8% of NeuroPace shares are held by institutional investors. 0.1% of Bluejay Diagnostics shares are held by company insiders. Comparatively, 20.5% of NeuroPace shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Profitability
This table compares Bluejay Diagnostics and NeuroPace’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Bluejay Diagnostics | N/A | -362.07% | -299.10% |
| NeuroPace | -29.29% | -168.61% | -25.48% |
Risk & Volatility
Bluejay Diagnostics has a beta of 0.59, suggesting that its share price is 41% less volatile than the S&P 500. Comparatively, NeuroPace has a beta of 1.9, suggesting that its share price is 90% more volatile than the S&P 500.
Analyst Recommendations
This is a breakdown of recent ratings for Bluejay Diagnostics and NeuroPace, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Bluejay Diagnostics | 1 | 0 | 0 | 0 | 1.00 |
| NeuroPace | 1 | 1 | 5 | 0 | 2.57 |
NeuroPace has a consensus target price of $16.60, suggesting a potential upside of 71.49%. Given NeuroPace’s stronger consensus rating and higher probable upside, analysts clearly believe NeuroPace is more favorable than Bluejay Diagnostics.
Summary
NeuroPace beats Bluejay Diagnostics on 10 of the 14 factors compared between the two stocks.
About Bluejay Diagnostics
Bluejay Diagnostics, Inc., a medical diagnostic company, develops rapid test for the monitoring of disease progression in the United States. It is developing Symphony platform, a technology platform comprising Symphony analyzer that orchestrates blood processing, biomarker isolation, and immunoassay preparation using non-contact centrifugal force; and Symphony Cartridge, which includes reagents and components. The company also offers ALLEREYE diagnostic test, a point-of-care device for the diagnosis of allergic conjunctivitis. In addition, it develops IL-6 for the monitoring of disease progression in critical care; as well as hsTNT/I and NT-proBNP for the monitoring of patients acuity with chest pain. The company was incorporated in 2015 and is headquartered in Acton, Massachusetts.
About NeuroPace
NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating medically refractory focal epilepsy. It also records continuous brain activity data and enables clinicians to monitor patients in person and remotely. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. The company sells its products to hospital facilities for initial RNS system implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.
Receive News & Ratings for Bluejay Diagnostics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bluejay Diagnostics and related companies with MarketBeat.com's FREE daily email newsletter.
